权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel insights into the molecular and cellular mechanism regulating lipid metabolism and atherosclerosis

对调节脂质代谢和动脉粥样硬化的分子和细胞机制的新见解

基本信息

批准号：
10551905
负责人：
Carlos Fernandez Hernando
金额：
$ 85.01万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-02-01 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10551905
关键词：
Animal Model Area Arteries Atherosclerosis Biogenesis Cardiometabolic Disease Cardiovascular Diseases Caveolae Cells Cholesterol Cholesterol Homeostasis Code Data Development Disease Electron Microscopy Event Gene Expression Genes Genetic High Density Lipoprotein Cholesterol High Density Lipoproteins In Vitro Infiltration Inflammation Inflammatory LDL Cholesterol Lipoproteins Lipids Lipoproteins Low-Density Lipoproteins Mediating Metabolic syndrome MicroRNAs Molecular Morbidity - disease rate Pathologic Processes Plasma Play Process Proteins Societies Techniques Therapeutic Untranslated RNA Work atherogenesis cardiovascular disorder risk caveolin 1 cholesterol control combat defined contribution epidemiology study glucose metabolism in vivo innovation insight lipid metabolism lipoprotein cholesterol mortality mouse model novel uptake

项目摘要

PROJECT SUMMARY Alterations in the control of cholesterol homeostasis can lead to pathological processes, including atherosclerosis, the most common cause of mortality in Western societies. Epidemiological studies have identified many environmental and genetic factors that contribute to atherogenesis. In particular, high levels of low-density lipoprotein cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C) are associated with increased cardiovascular disease (CVD) risk. In addition to protein coding genes, non- coding RNAs including microRNAs (miRNAs) have recently shown to play a key role in regulating gene expression. Alteration in miRNAs expression has been associated to numerous diseases including CVD. Our previous work has demonstrated the importance of miRNAs in regulating HDL-C and LDL-C. In particular, work from our group and others identified miR-33a/b and miR-148a as key regulators of cellular cholesterol efflux and uptake, HDL biogenesis and LDL clearance. While these studies highlight the therapeutic potential of manipulating miRNAs to control circulating HDL-C and LDL-C, the effect of both miRNAs in controlling lipid and glucose metabolism remains poorly understood. To investigate in depth the molecular mechanism by which miR-33a/b and miR-148a regulate glucose and lipid metabolism, we have recently developed a number of unique mouse models that will allow us to define the contribution of miR-33 and miR-148a in controlling lipid metabolism and atherogenesis in vivo. Using cutting-edge techniques, we will identify the regulatory network through which miR-33a/b and miR-148a regulate lipid metabolism both in vitro and in vivo, and assess the potential therapeutic value of anti-miR- 33a/b and antimiR-148a therapy for treating cardiometabolic diseases including atherosclerosis and metabolic syndrome. Additionally, we will continue our efforts to identify and characterize novel non-coding RNAs, including long non-coding RNAs (lncRNAs) that regulate lipid metabolism and other processes that influence the development of CVD. In another different topic, we will also study the molecular mechanisms that regulate the initial steps of atherogenesis. We hypothesize that Cav-1/caveolae expression is regulated by flow and mediates LDL infiltration and retention in atheroprone areas leading to the progression of atherosclerosis. Using unique animal models and innovative electron microscopy technics we aim to characterize how this process is regulated.

项目总结